search
Back to results

Heart Rate Variability in Response to Metformin Challenge

Primary Purpose

Fibromyalgia, Mitochondrial Diseases, Movement Disorders

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Metformin
Sponsored by
Woodinville Psychiatric Associates
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Fibromyalgia focused on measuring metformin, mitochondria, complex 1, fibromyalgia, neurogenic pain, diabetes, tardive dyskinesia, heart rate variability

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

EITHER chronic neurogenic pain meeting American College of Rheumatology criteria for fibromyalgia or previous/current exposure to antipsychotic medications

Exclusion Criteria:

  • recent infection,
  • renal failure,
  • pre-existing cardiac disease,
  • chronic obstructive pulmonary disease
  • inability to participate in informed consent,
  • lack of transport to return home from study site,
  • severe fasting intolerance or hypoglycemia,
  • history of stroke-alike episode,
  • uncontrolled migraine or cyclic vomiting,
  • diabetes on insulin or sulfonylurea,
  • non-English speaker,
  • medications with strong effects on baseline heart rate variability

Sites / Locations

  • Woodinville Psychiatric Associates

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Fibromyalgia

Antipsychotic use

Arm Description

Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning

Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning

Outcomes

Primary Outcome Measures

Heart Rate Variability (Time Domain)
ratio of the standard deviation of sampled intervals between each heart beat for ten minutes at time 1 (prior to metformin ingestion) over standard deviation of the sampled intervals between each heart beat for ten minutes at time 2 (2 hours post metformin ingestion)
Heart Rate Variability (Frequency Domain)
total power in the frequency domain is estimated for 10 minutes prior to metformin ingestion and then divided by the total power in the frequency domain estimated for 10 minutes 2 hours after metformin ingestion. Ratio is log-transformed.

Secondary Outcome Measures

Number of Patients Reporting Side Effects From the Medication
Patient after testing generated an unprompted list of observed side effects from the medication. Many reported none. Results were scored as the binary presence or absence of side effect

Full Information

First Posted
July 11, 2015
Last Updated
December 30, 2017
Sponsor
Woodinville Psychiatric Associates
search

1. Study Identification

Unique Protocol Identification Number
NCT02500628
Brief Title
Heart Rate Variability in Response to Metformin Challenge
Official Title
Heart Rate Variability in Response to Metformin Challenge
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
July 2015 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Woodinville Psychiatric Associates

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use). Patients with these possible mitochondrial disorders will provide a baseline resting heart rate sample, ingest low-dose metformin (500 mg), and then provide an additional sample 2 hours later.
Detailed Description
Doctors need to develop tests which inexpensively and reliably evaluates brain metabolism. Current diagnostic tests sample other tissues which often run on different fuels (fats), utilize unproven and often insensitive brain imaging scanners, or sequence thousands to millions of base-pairs of DNA. All of these tests are expensive. None of these tests accurately or completely capture the interactions between the 1000s of proteins involved in brain metabolism. The investigators suspect that mathematical analysis of the resting heart rate may provide some insight into brain metabolism. The brain controls heart rate in response to changes in blood pressure and blood gases like carbon dioxide and oxygen. Tight control of heart rate is necessary to make sure that the brain has the right mix of fuel and air. Because the brain can't respond instantly to changes in its fuel supply, this system acting as a biological carburetor has a natural oscillatory rhythm that can be monitored just like frequencies on the radio. The investigators propose to amplify these rhythms by modestly metabolically stressing the brain with metformin, a inhibitor of complex 1 in the mitochondria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
Keywords
metformin, mitochondria, complex 1, fibromyalgia, neurogenic pain, diabetes, tardive dyskinesia, heart rate variability

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fibromyalgia
Arm Type
Experimental
Arm Description
Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
Arm Title
Antipsychotic use
Arm Type
Experimental
Arm Description
Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Glucophage
Intervention Description
500 mg orally after baseline testing of heart rate
Primary Outcome Measure Information:
Title
Heart Rate Variability (Time Domain)
Description
ratio of the standard deviation of sampled intervals between each heart beat for ten minutes at time 1 (prior to metformin ingestion) over standard deviation of the sampled intervals between each heart beat for ten minutes at time 2 (2 hours post metformin ingestion)
Time Frame
difference pre/post metformin ingestion (2 hours)
Title
Heart Rate Variability (Frequency Domain)
Description
total power in the frequency domain is estimated for 10 minutes prior to metformin ingestion and then divided by the total power in the frequency domain estimated for 10 minutes 2 hours after metformin ingestion. Ratio is log-transformed.
Time Frame
difference pre/post metformin ingestion (2 hours)
Secondary Outcome Measure Information:
Title
Number of Patients Reporting Side Effects From the Medication
Description
Patient after testing generated an unprompted list of observed side effects from the medication. Many reported none. Results were scored as the binary presence or absence of side effect
Time Frame
2 hours after ingestion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: EITHER chronic neurogenic pain meeting American College of Rheumatology criteria for fibromyalgia or previous/current exposure to antipsychotic medications Exclusion Criteria: recent infection, renal failure, pre-existing cardiac disease, chronic obstructive pulmonary disease inability to participate in informed consent, lack of transport to return home from study site, severe fasting intolerance or hypoglycemia, history of stroke-alike episode, uncontrolled migraine or cyclic vomiting, diabetes on insulin or sulfonylurea, non-English speaker, medications with strong effects on baseline heart rate variability
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jon E Berner, MD PhD
Organizational Affiliation
Woodinville Psychiatric Associates
Official's Role
Principal Investigator
Facility Information:
Facility Name
Woodinville Psychiatric Associates
City
Woodinville
State/Province
Washington
ZIP/Postal Code
98072
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Heart Rate Variability in Response to Metformin Challenge

We'll reach out to this number within 24 hrs